PMID- 32329867
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 24
IP  - 7
DP  - 2020 Apr
TI  - Remifentanil improves myocardial ischemia-reperfusion injury in rats through 
      inhibiting IL-18 signaling pathway.
PG  - 3915-3922
LID - 20858 [pii]
LID - 10.26355/eurrev_202004_20858 [doi]
AB  - OBJECTIVE: To explore the protective effect of remifentanil against myocardial 
      ischemia-reperfusion injury (MIRI) in rats and its mechanism. MATERIALS AND 
      METHODS: The rat models of IRI were established and randomly divided into 1) 
      sham-operation group (S group), 2) IRI rat model group (M group), 3) low-dose 
      remifentanil group (R-L group), 4) moderate-dose remifentanil group (R-M group), 
      and 5) high-dose remifentanil group (R-H group). The rats in R-L group, R-M 
      group, and R-H group were administrated with remifentanil at 0.4 mug/kg/min, 2 
      mug/kg/min, and 10 mug/kg/min, respectively. The activity of creatine kinase-MB 
      (CK-MB), aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) in 
      myocardial cells was detected using the automatic biochemical analyzer, and the 
      apoptosis rate of myocardial cells was detected via terminal deoxynucleotidyl 
      transferase-mediated dUTP nick end labeling (TUNEL) assay. Moreover, the 
      messenger ribonucleic acid (mRNA) and protein levels of related cytokines in 
      myocardial cells were determined through quantitative Polymerase Chain Reaction 
      (qPCR) and Western blotting, and the content of interleukin-1beta (IL-1Symbol ) and 
      IL-18 in peripheral blood was detected via enzyme-linked immunosorbent assay 
      (ELISA). RESULTS: Remifentanil at different concentrations could protect 
      myocardium from IRI, and remifentanil at 2 mug/kg/min and 10 mug/kg/min could 
      significantly down-regulate the myocardial enzyme indexes in IRI myocardial cells 
      (p<0.01). Besides, remifentanil reduced the mRNA expressions of IL-18, INF-gamma, 
      TNF-beta, and IL-1beta (p<0.01), significantly decreased the protein expression of 
      IL-18, and raised the protein expression of IL-18BP, thereby improving myocardial 
      pathological damage. CONCLUSIONS: The protective mechanism of remifentanil on the 
      myocardium of MIRI rats may be related to the inhibition on the IL-18 signaling 
      pathway.
FAU - Ni, X-Q
AU  - Ni XQ
AD  - Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, China. 383836979@qq.com.
FAU - Hu, Z-Y
AU  - Hu ZY
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Interleukin-18)
RN  - P10582JYYK (Remifentanil)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Dose-Response Relationship, Drug
MH  - Interleukin-18/*antagonists & inhibitors/metabolism
MH  - Male
MH  - Myocardial Reperfusion Injury/*drug therapy/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Remifentanil/administration & dosage/*pharmacology
MH  - Signal Transduction/*drug effects
EDAT- 2020/04/25 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/04/25 06:00 [entrez]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - 20858 [pii]
AID - 10.26355/eurrev_202004_20858 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):3915-3922. doi: 
      10.26355/eurrev_202004_20858.